Walleye Capital’s Viridian Therapeutics VRDN Stock Holding History

Walleye Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200	Closed	-$6.22K	–	5036
2025 Q4	$6.22K	Hold	200	–	–	﹤0.01%	4326
2025 Q3	$4.32K	Buy	+200	New	+$3.61K	﹤0.01%	4325
2024 Q2	–	Sell	-3,600	Closed	-$63K	–	6050
2024 Q1	$63K	Sell	3,600 -2,000	-36%	-$38.8K	﹤0.01%	4595
2023 Q4	$122K	Buy	5,600 +5,100	+1,020%	+$80.5K	﹤0.01%	3962
2023 Q3	$7.67K	Buy	500 +200	+67%	+$3.81K	﹤0.01%	4520
2023 Q2	$7.14K	Sell	300 -4,600	-94%	-$118K	﹤0.01%	3970
2023 Q1	$125K	Buy	4,900 +2,000	+69%	+$64.1K	﹤0.01%	2800
2022 Q4	$84.7K	Buy	2,900 +1,400	+93%	+$32.3K	﹤0.01%	2408
2022 Q3	$31K	Buy	+1,500	New	+$27K	﹤0.01%	2668

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Walleye Capital's VRDN Position: Q2 2026 in Review

Walleye Capital sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 54,398 shares — an estimated $1.06M sold.

Walleye Capital first reported a position in VRDN in Q3 2021 and held it in 19 quarters. The position peaked at $12.7M in Q3 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Walleye Capital reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 54,398 Viridian Therapeutics shares in Q2 2026, an estimated $1.06M.
Walleye Capital first reported a position in Viridian Therapeutics in Q3 2021 and held it in 19 quarters.
Walleye Capital's Viridian Therapeutics position peaked at $12.7M in Q3 2024.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.